The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus

Gestational diabetes mellitus (GDM) affects a significant percentage of pregnancies worldwide and carries risks for both mother and baby. Finding safe and effective treatments is a clinical priority. This study by Yin, Pan, He, and colleagues, published in Pharmacological Research, investigated whether MOTS-c could address the hyperglycemia and insulin resistance characteristic of GDM.

The researchers used preclinical models of gestational diabetes to test MOTS-c's effects on blood glucose levels, insulin sensitivity, and related metabolic parameters. They examined both the efficacy and the mechanisms through which MOTS-c exerts its metabolic benefits in the context of pregnancy-related metabolic dysfunction.

The findings were encouraging: MOTS-c treatment significantly relieved hyperglycemia and improved insulin resistance in the gestational diabetes models. The peptide's metabolic benefits were robust, suggesting meaningful therapeutic potential for managing one of the most common complications of pregnancy.

This research expands the clinical relevance of MOTS-c to a population with particularly urgent need for safe, effective metabolic interventions. While more research is needed before clinical application, the demonstration that MOTS-c can improve metabolic function in the context of gestational diabetes underscores the peptide's broad applicability as a metabolic regulator.